CRASH-2 study證明transamine打的有道理，不過減少因為bleeding造成的risk 實在不多

Tranexamic Acid Reduces Mortality After Major Trauma

This promising new therapy is inexpensive and easy to administer.

The antifibrinolytic agent tranexamic acid has been shown to decrease blood loss and transfusion requirements during surgery. In the randomized, controlled, partly industry-funded international CRASH-2 (Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage 2) trial, researchers evaluated the effect of tranexamic acid on outcomes in 20,211 adult trauma patients with (or at risk for) bleeding. Tranexamic acid (loading dose of 1 g during 10 minutes followed by infusion of 1 g during 8 hours) or placebo was administered within 8 hours of injury.

The rate of in-hospital mortality from all causes within 4 weeks of injury was significantly lower in the tranexamic acid group than in the placebo group (14.5% vs. 16.0%; relative risk, 0.91). Risk for hemorrhagic death was also reduced (4.9% vs. 5.7%; RR, 0.85). About half the patients in each group received blood product transfusions. The incidence of vascular occlusive events (myocardial infarction, stroke, pulmonary embolism, deep venous thrombosis) was similar in the two groups (about 2%). No unexpected or serious adverse events attributed to the study drug occurred.

Comment: Tranexamic acid is inexpensive, is simple to administer, and has the potential to reduce mortality from hemorrhage following traumatic injury. On the basis of the results of this large, well-designed, international study, centers caring for trauma patients should review their protocols and consider adding tranexamic acid for patients with active hemorrhage or significant risk for recurrent or ongoing bleeding.

— Kristi L. Koenig, MD, FACEP

Published in Journal Watch Emergency Medicine June 15, 2010

Citation(s):

CRASH-2 trial collaborators. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): A randomised, placebo-controlled trial. Lancet 2010 Jun 15; [e-pub ahead of print]. (http://dx.doi.org/10.1016/S0140-6736(10)60835-5)

Levy JH. Antifibrinolytic therapy: New data and new concepts. Lancet 2010 Jun 15; [e-pub ahead of print]. (http://dx.doi.org/10.1016/S0140-6736(10)60939-7)


http://docs.google.com/fileview?id=0B278nGJMQBk7YmM2YjViOWUtYjVhNS00YTQwLWFmMTItNjgwOTgyNmM4M2Q3&hl=en

留言

張貼留言

這個網誌中的熱門文章

即便是用IGRA, 有時也要等大於三個月才能決定TB contact

圖片
接觸TB後，TST大抵上2-12週轉陽，IGRA大抵上6-10週，但IGRA可以長到3個月以上 TB Tests Can Have a Lengthy Window Period Two studies suggest that interferon- release assay conversion sometimes occurs more than 3 months after exposure to active tuberculosis. Increasingly, interferon- release assays (IGRAs) are being used for diagnosing latent tuberculosis (TB). Although the tuberculin skin test (TST) traditionally used for this purpose converts to positive within 2 to 12 weeks after an individual is exposed to someone with active TB, the interval for IGRA conversion has remained unclear. Current guidelines recommend repeating an initially negative IGRA after 6 to 10 weeks, but this recommendation is not based on controlled studies. Two recent investigations address this issue. Anibarro and colleagues conducted a longitudinal prospective analysis among contacts of TB patients in Spain. The 152 contacts received a TST and an IGRA at first visit; for individuals with negative or conflicting results, t
閱讀完整內容

early vs late tracheostomy, 早切不會降低死亡率，不會降低VAP，不會降低LOS, wait!

April 27, 2010 — Early vs late tracheotomy (6 - 8 days vs 13 - 15 days after mechanical ventilation) may not significantly lower the risk for ventilator-associated pneumonia in adult patients in the intensive care unit (ICU), according to the results of a randomized controlled trial reported in the April 21 issue of the Journal of the American Medical Association . "Tracheotomy is used to replace endotracheal intubation in patients requiring prolonged ventilation; however, there is considerable variability in the time considered optimal for performing tracheotomy," write Pier Paolo Terragni, MD, from Università di Torino in Turin, Italy, and colleagues. "This is of clinical importance because timing is a key criterion for performing a tracheotomy and patients who receive one require a large amount of health care resources." The goal of this study was to compare early tracheotomy vs late tracheotomy in the incide
閱讀完整內容